

Infertility

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit	Comments
Cetrotide	N/A	N/A
Clomiphene Citrate	N/A	N/A
Crinone 8%	1 applicator per day	In women with partial or complete ovarian failure who require progesterone replacement, 2 applicators per day may be approved. Override criteria only apply to benefits with fertility coverage.
Endometrin	N/A	N/A
Follistim AQ (non-preferred follicle stimulating hormone agent)	N/A	N/A
Ganirelix	N/A	N/A
Gonal-F (preferred follicle stimulating hormone agent)	N/A	N/A
Gonal-F RFF (preferred follicle stimulating hormone agent)	N/A	N/A
Leuprolide acetate (immediate release)	N/A	See note below
Lupron Depot (1 month) (leuprolide acetate) 3.75mg	1 per 4 weeks	See note below
Lupron Depot (1 month) (leuprolide acetate) 7.5mg	1 per 4 weeks	See note below
Lupron Depot (3 month) (leuprolide acetate) 11.25mg and 22.5mg	1 kit per 12 weeks	See note below
Lupron Depot (4 month) (leuprolide acetate) 30mg	1 per 16 weeks	See note below
Lupron Depot (6 month) (leuprolide acetate) 45mg	1 per 24 weeks	See note below

Menopur	N/A	N/A
Novarel	N/A	N/A
Ovidrel	N/A	N/A
Pregnyl	N/A	N/A

*****Note: For Leuprolide acetate (immediate release) or Lupron Depot request other than infertility please see the separate clinical criteria document (GnRH Clinical Criteria) detailing that specific approval criteria*****

Clomiphene Citrate

Requests for clomiphene citrate may be approved for 6 cycles of therapy for ovulation induction in an individual if the following criteria are met:

- I. Individual has a diagnosis of normogonadotropin anovulatory dysfunction including polycystic ovary syndrome; **OR**
- II. Individual has a diagnosis of unexplained infertility of short duration with normal levels of luteal progesterone and a normal hysterosalpingogram; **OR**
- III. Individual has a diagnosis of Stage I or II endometriosis.

Requests for clomiphene citrate may not be approved for any of the following:

- I. Primary ovarian failure or tubal occlusion; **OR**
- II. Hypogonadotropic anovulatory disorders or hypopituitarism; **OR**
- III. Received greater than 6 cycles of therapy.

Injectable Follicle Stimulating Hormones (Follistim AQ, Gonal-f, Gonal-f-RFF, or Menopur (menotropins) for Ovarian Stimulation Alone or with Intrauterine Insemination

Requests for Follistim AQ, Gonal-f, Gonal-f-RFF, or Menopur may be approved for a maximum of 3 cycles, with or without intrauterine insemination in an infertile* individual if the following criteria are met:

- I. Individual has a diagnosis of hypogonadotropin anovulatory disorders or hypopituitarism (these individuals will not respond to follicle stimulating hormone alone, but will require additional therapy with an luteinizing hormone containing product such as human chorionic gonadotropin or will use a mixed follicle stimulating hormone/luteinizing hormone product like Menopur); **OR**
- II. Individual has a diagnosis of normogonadotropin anovulatory disorders (including polycystic ovary syndrome) or those with unexplained infertility* who have not ovulated or conceived after a prior trial of 3 cycles of clomiphene.

Requests for ovarian induction with Follicle Stimulating Hormones or Menopur (menotropins) may not be approved for the following:

- I. Individual is receiving more than 3 ovulatory cycles of therapy; **OR**
- II. Individual has a diagnosis of tubal occlusion or primary ovarian failure.

Injectable Follicle Stimulating Hormones (Follistim AQ, Gonal-f, Gonal-f-RFF, or Menopur (menotropins) for Ovarian Stimulation in Conjunction with In Vitro Fertilization or Intracytoplasmic Sperm Injection

Requests for Follistim AQ, Gonal-f, Gonal-f-RFF, Menopur, Ovidrel (recombinant human chorionic gonadotropin) or Pregnyl, Novarel (urinary derived human chorionic gonadotropins), with Lupron Depot or leuprolide acetate (immediate release) (gonadotropin releasing hormone agonists) or Cetrotide, Ganirelix (gonadotropin releasing hormone antagonists) may be approved for a maximum of 3 cycles of ovarian stimulation in conjunction with in vitro fertilization or intracytoplasmic sperm injection in an infertile* individual or couple if the following criteria are met:

- I. The couple has a diagnosis of severe male factor infertility; **OR**
- II. The individual has a diagnosis of bilateral tubal occlusion; **OR**
- III. The individual has a diagnosis of unexplained infertility that has not responded to ovarian induction therapy.

Injectable Follicle Stimulating Hormones (Follistim AQ, Gonal-f, Gonal-f-RFF, Menopur (menotropins), Pregnyl, Novarel (urinary derived human chorionic gonadotropins)), Lupron Depot, leuprolide acetate (immediate release) (gonadotropin releasing hormone agonists), or Cetrotide, Ganirelix (gonadotropin releasing hormone antagonists) for Preservation of Fertility

Requests for Injectable Follicle Stimulating Hormones (Follistim AQ, Gonal-f, Gonal-f-RFF, Menopur (menotropins), Pregnyl, Novarel (urinary derived human chorionic gonadotropins)), Lupron Depot, leuprolide acetate (immediate release) (gonadotropin releasing hormone agonists), or Cetrotide, Ganirelix (gonadotropin releasing hormone antagonists) may be approved if the following criteria are met:

- I. Individual is using in the preservation of fertility in pre-menopausal women; **AND**
- II. Individual currently has a cancer diagnosis; **AND**
- III. Individual meets one of the following:
 - A. Individual will receive chemotherapy for cancer with a curative intent; **OR**
 - B. Individual will receive radiation therapy for cancer with a curative intent.

Injectable Follicle Stimulating Hormones (Follistim AQ, Gonal-f) for Male Infertility Associated with Hypogonadotropic Hypogonadism

Requests for Follistim AQ or Gonal-F in combination with human chorionic gonadotropins in an infertile* individual may be approved if the following criteria are met:

- I. Individual has a diagnosis of hypogonadotropic hypogonadism with onset prior to completion of pubertal development.

Requests for the use of human chorionic gonadotropin alone or in combination with follicle stimulating hormone may be approved if the following criteria are met:

- I. Individual is using to maintain spermatogenesis for an infertile individual with post-pubertal acquired hypogonadotropic hypogonadism who have previously had normal sperm production.

Requests for the use of human chorionic gonadotropin alone or in combination with follicle stimulating hormone may be approved if the following criteria are met:

- I. Individual is using to maintain spermatogenesis for an infertile individual with partial gonadotropin deficiency.

Progesterone Vaginal Supplementation or Replacement for Infertility Treatment -- Crinone 8% gel, Endometrin vaginal insert

Requests for Crinone 8% gel or Endometrin vaginal insert may be approved if the following criteria are met:

- I. Individual is using as part of an Assisted Reproductive Technology treatment; **AND**
- II. Individual has a diagnosis of infertility*; **AND**
- III. Individual requires progesterone supplementation.

The use of progesterone 4% gel may not be approved as part of an Assisted Reproductive Technology treatment for an infertile individual who requires progesterone supplementation.

*Note: For the purposes of this document, infertility is defined clinically in women and men who cannot achieve a successful pregnancy after 12 months or more of appropriate, timed unprotected intercourse or 6 cycles of therapeutic donor insemination. The diagnosis of male or female infertility requires evaluation of the couple versus a single individual.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 26, 2021.
3. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA*. 2011; 306(3):269-276.
4. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. *Cancer Treat Rev*. 2014; 40(5):675-683.
5. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
6. Gerber B, von Minckwitz G, Stehle H, et al.; German Breast Group Investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. *J Clin Oncol*. 2011; 29(17):2334-2341.
7. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.

8. Moore HC, Unger JM, Phillips KA, et al; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*. 2015; 372(10):923-932.
9. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients, 2002 update. *Endocr Pract*. 2002; 8:439-456.
10. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. *Fertil Steril*. 2014;101(3):633-634.
11. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914.
12. Vitek WS, Shayne M, Hoeger K, et al. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. *Fertil Steril*. 2014; 102(3):808-815.
13. NCCN Clinical Practice Guidelines in Oncology™. ©2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on November 20, 2021.
 - a. Adolescent and Young Adult Oncology V2.2022. Revised November 22, 2021.
 - b. Breast Cancer. V1.2022. Revised November 24, 2021.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.